HeartFlow has revealed that seven new commercial payers issued positive medical policies covering the use of the HeartFlow FFRct analysis following a coronary computed tomography angiogram. A press release reports that the HeartFlow analysis is a non-invasive technology that creates a personalised 3D model of the heart and simulates blood flow to help clinicians diagnose and treat patients with suspected heart disease.
The positive medical policies were issued by Cigna; Florida Blue; the Blue Cross and Blue Shield plans of Michigan, North Carolina, and Vermont; Highmark, Inc.; and Independence Blue Cross. Commercial coverage for the HeartFlow analysis is now available for approximately 130 million patients, in addition to the Centers for Medicare & Medicaid Services (CMS) recent decision to assign a New Technology APC payment for the HeartFlow FFRct Analysis for more than 55 million Medicare beneficiaries.
John H Stevens, president and chief executive officer of HeartFlow, comments: “These positive coverage decisions reinforce the clinical and economic value of the HeartFlow analysis in addressing how heart disease is diagnosed and treated. With the growing momentum of coverage, a wealth of scientific evidence, and unparalleled technology, the HeartFlow analysis is poised to become the standard of care for patients with suspected heart disease.”
